Breakthrough Cancer Diagnosis Technology Developed by EDGC Using AI
EDGC (Eone Diagnomics) has announced groundbreaking research results that have significantly improved the accuracy of cancer diagnosis. This achievement was made possible through the use of their multi-omics genome analysis platform based on AI technology. The development of AI has paved the way for the possibility of early cancer diagnosis using a simple blood test.
The research findings have been published in the September issue of ‘Cancer’, a prestigious journal listed in SCIE, the international science and technology citation index. The paper, titled ‘Improving Lung Cancer Classification by Integrating Liquid Biopsy Multi-Omic Data with Machine Learning Techniques’, highlights how EDGC has made significant advancements in cancer diagnosis accuracy through years of dedicated research.
According to the paper, EDGC’s proprietary artificial intelligence multi-omics platform has displayed higher accuracy than existing diagnostic methods for cancer. While the diagnostic methods using only cell-free DNA (cfDNA), gene copy number (CNV), or cancer markers individually showed accuracy levels below AUC 0.7 or 0.8, EDGC’s AI analysis achieved an accuracy of AUC 0.931. This means that lung cancer patients can be identified with a probability of approximately 93%, marking a remarkable breakthrough in cancer diagnosis.
Notably, the technology developed by EDGC can differentiate between early-stage and late-stage lung cancer patients. The multi-omics analysis method accurately distinguishes between stage 1 and 2 lung cancer patients with an AUC of 0.964, and stage 3 and 4 patients with an impressive AUC of 0.983. This equates to a probability of approximately 96.4% and 98.3% for diagnosing early-stage and late-stage cancer patients, respectively.
EDGC’s multi-omics analysis method presents a promising avenue for early cancer diagnosis. The institute’s high technological capabilities have garnered international attention and recognition. EDGC currently offers its OncoCatch-S technology, as presented in the research paper, in Germany, Panama, Turkey, and Vietnam. Expansion plans to other countries where the company operates are in progress. The OncoCatch-S Service is a multi-omics platform for diagnosing lung cancer, which integrates the analysis of cancer markers, cell-free DNA concentration, and gene copy number.
OncoCatch: A Revolutionary Diagnostic Technology
The OncoCatch technology developed by EDGC utilizes innovative NGS technology and bioinformatics to analyze tumor DNA circulating in the blood. It provides early cancer detection, cancer recurrence monitoring, and personalized targeted anticancer drug selection. The OncoCatch suite comprises four pipelines: OncoCatch-E, OncoCatch-S, OncoCatch-CDx, and OncoCatch-M, catering to different inspection purposes and methods.
- OncoCatch-E: This pipeline detects trace amounts of tumor DNA derived from cancer cells present in cell-free DNA (cfDNA). Methylation patterns associated with cancer development can be measured, and with the application of artificial intelligence algorithms, multiple cancers can be screened at an early stage.
- OncoCatch-CDx: Designed to support medical professionals, this pipeline provides customized anticancer drug prescriptions for all types of solid cancer to benefit cancer patients.
- OncoCatch-M: This premium service monitors cancer recurrence and metastasis, as well as assesses the effectiveness of anticancer treatments.
CEO of EDGC, Lee Min-seop, emphasized the distinctive nature of OncoCatch as a diagnostic technology that enables early cancer detection, ultimately improving patient survival rates and reducing treatment costs. The company aims to introduce comprehensive cancer diagnosis services and is dedicated to ongoing research in this field.
EDGC (Eone Diagnomics) announced research results that dramatically improved the accuracy of cancer diagnosis using a multi-omics genome analysis platform based on AI technology. [사진=EDGC]
[이뉴스투데이 이승준 기자] EDGC (Eone Diagnomics) announced research results that dramatically improved the accuracy of cancer diagnosis using a multi-omics genome analysis platform based on AI technology. With the development of AI technology, an era is expected when early cancer diagnosis is possible with a drop of blood.
The results of the research were published in the September issue of ‘Cancer’, a journal listed in SCIE, the international science and technology citation index. The title of this paper is ‘Improving Lung Cancer Classification by Integrating Liquid Biopsy Multi-Omic Data with Machine Learning Techniques’, and it is a paper on how EDGC has improved the accuracy of cancer diagnosis through long-term research. We present research results that have dramatically improved results.
According to the paper, the accuracy of cancer analysis through EDGC’s proprietary artificial intelligence multi-omics platform recorded higher accuracy compared to independent diagnostic methods related to cancer diagnosis. Only cell-free DNA (cfDNA) diagnostic method recorded below AUC level 0.7, only gene copy number (CNV) diagnostic method recorded below AUC level 0.8, and only cancer marker diagnostic method recorded to record below the level of AUC 0.7, compared to the independent artificial intelligence EDGC The accuracy of analysis improved to AUC 0.931. This figure means that lung cancer patients can be distinguished from normal people with a probability of about 93%. This is a very high accuracy in the field of cancer diagnosis and is considered a breakthrough cancer diagnosis technology.
It is also worth noting that this technology can differentiate between patients with early stage lung cancer and those with late stage lung cancer. The EDGC multi-omics analysis method can differentiate between early stage lung cancer patients (stages 1 and 2) with an accuracy of AUC 0.964, and late stage lung cancer patients (stages 3 and 4) with a high accuracy of AUC 0.983. This means that early stage and late stage cancer patients can be diagnosed with a probability of approximately 96.4% and 98.3%.
Early cancer diagnosis is possible through the EDGC multi-omics analysis method. EDGC attracts international attention by proving the high technological capability of EDGC with the research results of this multi-omics analysis method developed exclusively with the institute’s own technology.
EDGC currently serves the OncoCatch-S technology presented in the paper in Germany, Panama, Turkey and Vietnam, and plans to gradually expand its presence in the countries in which it operates. The OncoCatch-S Service is a lung cancer diagnosis multi-omics platform that integrates analysis of cancer markers, cell-free DNA (cfDNA) concentration, and gene copy number (CNV).
EDGC’s OncoCatch is a technology that analyzes tumor DNA circulating in the blood using innovative NGS technology and bioinformatics technology. It can be used to detect cancer early, check for cancer recurrence, and select tailored targeted anticancer drugs. OncoCatch has four pipelines: OncoCatch-E, OncoCatch-S, OncoCatch-CDx, and OncoCatch-M, depending on the purpose and method of inspection.
OncoCatch-E can detect circulating tumor DNA derived from cancer cells that exists in trace amounts in cell-free DNA (cfDNA). It is possible to measure methylation patterns, which are epigenetic changes associated with the development of cancer, and by applying artificial intelligence algorithms, multiple cancers can be screened at a very early stage. OncoCatch-CDx supports medical staff with customized anticancer drug prescriptions for all types of solid cancer for cancer patients. OncoCatch-M is a premium service that monitors cancer recurrence, metastasis, and determines the effectiveness of anticancer treatment.
Lee Min-seop, CEO of EDGC, said, “OncoCatch is a very distinctive diagnostic technology in that it can detect cancer early, increase the survival rate of patients, and reduce treatment costs.” “We intend to introduce a cancer diagnosis service and we are focusing our abilities on research for this purpose,” he said.
#EDGC #unveils #technology #dramatically #improve #cancer #diagnosis #accuracy #global #cancer #journal